ClinicalTrials.gg
RecruitingNCT07163091BAFUpdated Apr 29, 2026

Bracing After Ankle Fracture

An interventional study of ankel stirrup and Foot-ankel brace (walker) in Ankle Fracture, Rehabilitation and Recovery, sponsored by Odense University Hospital. Recruiting at 16 sites in 2 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-04-29.

Sponsored by Odense University Hospital · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Apr 2026; still recruiting 6 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
1,400
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 11 studies in Ankle Fractures with a site in Denmark — 2 open to participants now, 2 under way, none of them phase 3. Ankle Fractures · Denmark.

Started
2026
with 1 other
No phase
7 of 11
2 open now
Registered
10th of 11
by date
Lead sponsor
2 of 11
Odense University Hospital

Among the 11 studies in Ankle Fractures with a site in Denmark, this one is one of 2 that started in 2026, is one of 7 with no phase, and was the 10th registered.

Ankle Fractures

203 studies on the registry are indexed under Ankle Fractures; 45 are open to participants now.

Browse Ankle Fractures studies →

Open to participants now

2 of the 11 studies in Ankle Fractures with a site in Denmark are open now. Recruiting first, the newest first:

All 2 open studies →

A study can be open while its sites in Denmark have not opened yet or have stopped. Only those recruiting at a site in Denmark →

Who these studies take

Of the 31 Ankle Fractures studies recruiting now, 14 (45%) set no upper age limit and 12 (39%) stop at 75 or younger; 4 take children under 18; 3 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 11 studies in Ankle Fractures with a site in Denmark, or all of them as a file.
02

Study summary

Ankle fractures are common, debilitating and usually treated with immobilisation using a foot-ankle brace (walker). Emerging evidence suggests that a less restrictive brace may reduce recovery time without increasing the risk of complications, and patients tend to prefer ankle stirrups. However, evidence supporting their non-inferiority remains limited and inconclusive. Thus, the aim is assess if an ankle stirrup is non-inferior to a standard walker in reducing pain and function measured by the Manchester-Oxford Foot Questionnaire (MOXFQ) three months after ankle fracture. The hypothesis is that ankel stirrups align better with patients preferenes for less immobilising braces and offer sufficient stability while the fracture heals. Secondarily it may lead to faster recovery of function, return to work and reduced cost. The sample size of a maximum of 1400 patients allow us to assess non-inferiority in age and sex specific subgroups and treatment (surgical or non-sugical). Non-inferiority will be assessed in a pragmatic, multicenter, randomised controlled trial involving Scandinavian orthopedic departments.

Read the detailed description

Ankle fractures are the third most occuring fracture. After an ankle fracture, patients experience reduced ankle function and pain [3]. Also, evidence with moderate to high risk of bias indicate that immobilisation prolong patients recovery. However, high quality evidence are necessary for finite conclusions.

In Scandinavia, foot-ankle braces (walkers) are used to immobilise the fracture while healing. Even though patients acknowledge the need for immobilisation, a qualitative study of ten patients found that patients experienced difficulties in adhering to the recommendation of immobilisation after ankle fracture. A randomised controlled trial (RCT) by Smeeing et al. 2020 found that braces and elastic bands that allow more ankle movement than walkers did not lead to poorer functional outcomes (p=0.56), but may lead to a faster return to work (p = 0.02) without increased complications (p=0.63). The RCT was terminated when half the sample had been included, thus questioning the statistical power of the findings. Based on patient interviews completed during trial preparations we learned that patients preferred ankle stirrups as they allowed movement during use. The same patients also expressed an aversion to the walker, while being hesitant that ankle-supporting elastic bandages provided sufficient support.

Compared to the walker, ankle stirrups may better align with patient preferences while remaining non-inferior in restoring ankle-related outcomes such as pain and function.

Patients will be included in the orthopedic outpatient departments and randomised to a walker or an ankle stirrup. Randomisation will be in blocks to ensure that surgically and non-surgically patients are evenly distributed between groups and that each center will have an equal amount of intervention and control patients. Weightbearing will be unrestricted in both groups so the difference will be the brace (ankel stirrup or walker). Other variation will be a reflection of usual practice. The primary outcome is a validated score including pain, function and social interaction 12 weeks after ankel fracture. The sample size is calculated to 140 patients per each of six subgroups (males 18-39, females 18-39, males 40-59, females 40-59, males 60+, females 60+) randomisation stop when the smallest subgroup (females 18-39 years) reaches 140 or a maximum of 1400 has been included. Patients have been involved in designing the trial and a former ankle fracture patient serves a member of the steering committee.

03

Conditions studied

  • Ankle Fracture
  • Rehabilitation
  • Recovery

Browse trials for

Keywords

  • ankle fracture
  • Brace
  • walker
  • ankle stirrup
  • intervention
  • RCT
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • 18 years or older
  • Surgically or non-surgically treated ankle fracture

Exclusion criteria

Exclusion Criteria:

  • Pathological fractures
  • Inadequacy to read or speak danish
  • Open fractures
  • Prolonged need for immobilisation (e.g. non-union or insufficient wound healing)
  • Inability to adhere to trial procedures (e.g. neuropathy or severe psychiatric disorder)
  • Restricted weightbearing
  • Uninterest in participating
05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Investigator)
Enrollment
1,400 participants (estimated)

Study arms

  • Active comparator
    foot ankel brace (walker)

    Walker: immobilisation during use

    Other: Foot-ankel brace (walker)

  • Experimental
    Ankel stirrup

    Ankel stirrup: active ankel dorsal and plantar flextion during use

    Other: ankel stirrup

Interventions

  • Otherankel stirrup

    Ankel stirrups are a patient preferred ankel brace that allow active ankle dorsal and plantar flexion during weightbearing while maintaining lateral stability.

  • OtherFoot-ankel brace (walker)

    Walkers immobilise and stabilise the ankle during weightbearing.

06

What researchers measure

Primary outcomes

  1. Index score (0-100) of the Manchester-Oxford Foot Questionnaire (MOXFQ)

    The index score of the Manchester-Oxford Foot Questionnaire (MOXFQ) three months after randomisation is chosen as the primary outcome. Patients prefer MOXFQ, and it is a valid and reliable self-administered 16-item patient-reported outcome (PRO) divided into three dimensions (walking/standing seven items, pain five items and social interaction four items). MOXFQ will be summarised as an index score covering the most important dimensions patients indicated after ankle fracture (e.g. pain, function and social interaction). Response options consist of a 5-point Likert scale ranging from zero to four. The MOXFQ index score will be calculated by summing the raw scores of the 16 items of the MOXFQ to a index score ranging from a minimum of 0 to a maximum of 100, where 100 represents the most severe health state.

    Time frame: Measured as the change from baseline and after 6 and 12 weeks

Secondary outcomes

  1. Physical activity

    The short-form International Physical Activity Questionnaire (IPAQ-SF) measure physical activity in five domains, including work-related physical activity, transportation, housework, leisure time and time spent sitting. Patients will be grouped into low, moderate and high physical activity levels depending on activities and time spent doing these activities.

    Time frame: Measured as the change from baseline and after 6 and 12 weeks

  2. Health-related Quality Of Life (HRQOL)

    HRQOL will be measured using the EuroQol five-dimension five-level questionnaire (ed-5d-5l)

    Time frame: Measured as the change from baseline and after 6 and 12 weeks

  3. Ankle dorsiflexion

    is measured using the knee-to-wall test, which measures ankle mobility in degrees of motion in standing.

    Time frame: Measured as the change from baseline and after 6 and 12 weeks

  4. Ankle strength

    is measured using the heel rise test. Patients perform as many single-leg heel raises at a cadence of one per second until fatigue or a maximum of 50 is reached. The test is performed on both legs, and normal function is recovered if the difference in heel raises between legs is 10% or less.

    Time frame: Measured as the change from baseline and after 6 and 12 weeks

  5. Hospital costs

    Hospital Costs will be measured from a hospital perspective with a time horizon of three months and include cost of procedures and in-hospital activities.

    Time frame: Measured as the total cost from baseline and after 12 weeks

  6. Return to work

    Will be measured by asking patients what date they returned to work (full-time and part-time). Information on work-related physical requirements (e.g., blue-collar or white-collar workers) and usual employment status (e.g., retiree, unemployed, working) will also be collected.

    Time frame: From fracture and until date of return to work.

  7. Index score (0-100) of the Manchester-Oxford Foot Questionnaire (MOXFQ) in subgroups

    The index score of the Manchester-Oxford Foot Questionnaire (MOXFQ) three months after randomisation is chosen as the primary outcome. Patients prefer MOXFQ, and it is a valid and reliable self-administered 16-item patient-reported outcome (PRO) divided into three dimensions (walking/standing seven items, pain five items and social interaction four items). MOXFQ will be summarised as an index score covering the most important dimensions patients indicated after ankle fracture (e.g. pain, function and social interaction). Response options consist of a 5-point Likert scale ranging from zero to four. The MOXFQ index score will be calculated by summing the raw scores of the 16 items of the MOXFQ to a index score ranging from a minimum of 0 to a maximum of 100, where 100 represents the most severe health state and analysed in subgroups: males 18-39, females 18-39, males 40-59, females 40-59, males 60+, females 60+ and in treatment groups (surgical and non-surgical)

    Time frame: Measured as the change from baseline after 6 and 12 weeks.

  8. Adverse Events (AE) and Serious Adverse Events (SAE)

    Adverse events are undesirable experiences that may occur during brace use as: i) skin irritation, blisters, or pressure sores due to poor fit, friction, or prolonged use, ii) swelling or increased edema, iii) pain or discomfort resulting from tightness, misalignment, or mechanical pressure, iv) delayed fracture healing due to excessive joint movement, v) Muscle atrophy or joint stiffness from immobilization, vi) reduced range of motion (ROM) and vii) removal of material (e.g., screws) due to discomfort or healing complications. Serious adverse events are complications requiring hospitalisation, surgical intervention, or posing a significant risk to the patient as i) death (e.g., an unexpected cardiac event occurring during the study period) ii) hospitalisation due to falls resulting from brace-related instability, iii) wound infection requiring inpatient treatment, potentially related to brace-induced i

    Time frame: Safety reporting for each patient will begin at baseline and after 6 and twelve weeks

Other outcomes

  1. The index score of the Manchester-Oxford Foot Questionnaire (MOXFQ)

    The index score of the Manchester-Oxford Foot Questionnaire (MOXFQ) three months after randomisation is chosen as the primary outcome. Patients prefer MOXFQ, and it is a valid and reliable self-administered 16-item patient-reported outcome (PRO) divided into three dimensions (walking/standing seven items, pain five items and social interaction four items). MOXFQ will be summarised as an index score covering the most important dimensions patients indicated after ankle fracture (e.g. pain, function and social interaction). Response options consist of a 5-point Likert scale ranging from zero to four. The MOXFQ index score will be calculated by summing the raw scores of the 16 items of the MOXFQ to a index score ranging from a minimum of 0 to a maximum of 100, where 100 represents the most severe health state.

    Time frame: Change from baseline to 6 and 12 months follow-up

  2. Physical activity long term

    Physical activity will be measured in longer term using the short-form International Physical Activity Questionnaire (IPAQ-SF) and grouping patients into low, moderate and high physical activity levels.

    Time frame: Change from baseline and after 6 and 12 months

  3. Health-related Quality Of Life (HRQOL) long term

    Long term Health-related Quality Of Life (HRQOL) will be measured using the EuroQol five-dimension five-level questionnaire (ed-5d-5l)

    Time frame: Baseline and after 6 and 12 months

  4. The index score of the Manchester-Oxford Foot Questionnaire (MOXFQ) in subgroups long term

    The index score of the Manchester-Oxford Foot Questionnaire (MOXFQ) three months after randomisation is chosen as the primary outcome. Patients prefer MOXFQ, and it is a valid and reliable self-administered 16-item patient-reported outcome (PRO) divided into three dimensions (walking/standing seven items, pain five items and social interaction four items). MOXFQ will be summarised as an index score covering the most important dimensions patients indicated after ankle fracture (e.g. pain, function and social interaction). Response options consist of a 5-point Likert scale ranging from zero to four. The MOXFQ index score will be calculated by summing the raw scores of the 16 items of the MOXFQ to a index score ranging from a minimum of 0 to a maximum of 100, where 100 represents the most severe health state and analysed in subgroups: males 18-39, females 18-39, males 40-59, females 40-59, males 60+, females 60+ and in treatment groups (surgical and non-surgical)

    Time frame: Change from baseline and after 6 and 12 months

  5. Incremental cost per quality adjusted life year gain

    cost-utility analysis will be completed alongside the clinical trial. Reporting will be from a societal perspective and with an one year timeframe. Utility will be measured in Quality Adjusted Life Years (QALY) by assigning values from the Danish eq-5d-5l reference set (i.e. each health state is assigned a value between -0.759 to 1.000 \[40\]. The follow-up period will be one year (t4). Costs will be collected from national registris. These, among others, include information on admissions, out-patient visits, home care services, contacts with general practitioners and other private healthcare professionals, prescription medication and welfare subsidies due to sick leave. Hours of informal care the last week patients receive from family and friends will be collected from patients at every follow-up (t1-t4). The reported amount will be assumed stable between time points. Valuation will based on the recommendations of the Health Technology Council and reported in euros (€) using the most

    Time frame: one year from baseline

  6. carbon footprint of the trial

    Carbon footprint of the BAF trial will be estimated by registrering activities associated with design, management and operation of the trial and summing the carbon of to estimate the overall carbon footprint (kgCO2e) using the Clinical Trial Carbon Calculator. Registered activities will be: cradle to gate estimate of ankle stirrups and foot-ankle braces, patients visits to hospital, mean of transportation to visits (car, public or bike, trial staff travel and mean of transportation to recruitments centers.

    Time frame: From baseline and after 6 and 12 weeks

  7. Adverse Events and Serious Adverse Events (SAE) long term

    Adverse events are undesirable experiences that may occur during brace use as: i) skin irritation, blisters, or pressure sores due to poor fit, friction, or prolonged use, ii) swelling or increased edema, iii) pain or discomfort resulting from tightness, misalignment, or mechanical pressure, iv) delayed fracture healing due to excessive joint movement, v) Muscle atrophy or joint stiffness from immobilization, vi) reduced range of motion (ROM) and vii) removal of material (e.g., screws) due to discomfort or healing complications. Serious adverse events are complications requiring hospitalisation, surgical intervention, or posing a significant risk to the patient as i) death (e.g., an unexpected cardiac event occurring during the study period) ii) hospitalisation due to falls resulting from brace-related instability, iii) wound infection requiring inpatient treatment, potentially

    Time frame: Safety reporting for each patient will begin at baseline and after 6 and 12 months

  8. Physical activity

    A subgroup of patients will have their physical activity objectively evaluated using an accelerometer. The SENS Accelerometer is widely used and validated for young and older orthopedic patients. The accelerometer measures total accelerometer counts per day (a valid proxy for physical activity), rest time, standing time, active time (walking time, running, cycling), number of steps, movement intensity and sleep duration for four weeks. The total amount of accelerometer counts will be used to measure the level of physical activity between groups \[39\]. The accelerometer will be placed on the patients thigh at the day of randomization and followed for a minimum of 12 weeks.

    Time frame: From baseline and for a minimum of 12 weeks

07

Study locations

4 of 16 sites recruiting
  • Orthopedic Department, Hospital of Southern Jutland
    Aabenraa, 6200, Denmark
    Not yet recruiting
  • Orthopedic Department, Aalborg Universitets Hospital
    Aalborg, 9000, Denmark
    Not yet recruiting
  • Orthopedic Department, Aarhus University Hospital
    Aarhus, 8200, Denmark
    Recruiting
  • Orthopedic Department, Bispebjerg Hospital
    Copenhagen, 2200, Denmark
    Not yet recruiting
  • Orthopedic Department, Hospital of South West Jutland
    Esbjerg, 6700, Denmark
    Not yet recruiting
  • Orthopedic Department, Herlev Hospital
    Herlev, 2730, Denmark
    Not yet recruiting
  • Orthopedic Department, North Zealand Hospital
    Hillerød, 3400, Denmark
    Not yet recruiting
  • Orthopedic Department, Hvidovre Hospital
    Hvidovre, 2650, Denmark
    Not yet recruiting
  • Orthopedic Department, Hospital Lillebaelt - Kolding
    Kolding, 6000, Denmark
    Recruiting
    • Jonas A Ipsen, phd · ContactJonas.Ammundsen.Ipsen@rsyd.dk · +4523925264
    • Lars Rottwitt, MD phd · Principal investigator
    • Ane Simony, MD phd · Sub investigator
  • Orthopedic Department, Zealand University Hospital - Køge
    Køge, 4600, Denmark
    Recruiting
  • Orthopedic Department, Odense University Hospital
    Odense, 5000, Denmark
    Recruiting
  • Orthopedic Department, Randers Hospital
    Randers, 5930, Denmark
    Not yet recruiting
  • Orthopedic Department, Slagelse Hospital
    Slagelse, 4200, Denmark
    Not yet recruiting
  • Orthopedic Department, Hospital Lillebaelt - Vejle
    Vejle, 7100, Denmark
    Not yet recruiting
  • Orthopedic Department, Viborg Hospital
    Viborg, 8800, Denmark
    Not yet recruiting
  • Surgical Centre, National Hospital of the Faroe Islands
    Tórshavn, Faroe Islands
    Not yet recruiting
08

References and documents

Publications

  • Ipsen JA, Holsgaard-Larsen A, Abrahamsen C, Gundtoft PH, Costa M, Mikkelsen SS, Hrobjartsson A, Viberg B. A study protocol for a randomised trial of bracing after ankle fracture. Dan Med J. 2026 Mar 19;73(4):A09250748. doi: 10.61409/A09250748. PubMed 41978451 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — Access to individual de-identified participant data and related study documents (e.g. protocol, Statistical Analysis Plan (SAP), will be provided to anyone who wishes to access the data.

Supporting information: Study protocol, Statistical analysis plan

Time frame: Immediately following publication, no end date.

Access criteria: Any researcher, affiliated to an established institution

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Apr 2026 (actual). Primary completion is estimated for Sep 2028, 29 months after the start.

Of 69 non-industry interventional studies with no phase under Ankle Fractures, half reached primary completion within 44 months of starting (the median), counting those still running; a quarter within 23 and three quarters within 61. This study's planned 29 months is below that.

Counting every sponsor, half of 72 studies reached it within 45 months; a quarter within 23 and three quarters within 61.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 20, 2025
First posted
Sep 9, 2025
StartActual
Apr 23, 2026
Primary completionEst.
Sep 30, 2028
CompletionEst.
Sep 30, 2029
Last update
Apr 29, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 29, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07163091
Collaborators
Aalborg University Hospital, Randers Regional Hospital, Aarhus University Hospital, Viborg Regional Hospital, Hospital of Southern Jutland, Slagelse Hospital, Bispebjerg Hospital, Hvidovre University Hospital, Herlev Hospital, National Hospital of the Faroe Islands, Hospital of South West Jutland, Esbjerg, Denmark, Køge Hospital, Denmark, Sygehus Lillebaelt
Responsible party
Sponsor
First posted
Sep 9, 2025
Start date
Apr 23, 2026
Primary completion
Sep 30, 2028 (estimated)
Completion
Sep 30, 2029 (estimated)
Last update
Apr 29, 2026

Study contacts

Jonas A Ipsen, phd
Contact
Jonas.Ammundsen.Ipsen@rsyd.dk
+4523925264
Bjarke Viberg, Phd
Contact
bjarke.viberg@rsyd.dk
Bjarke Viberg, Phd
study chair · Odense Universitetshospital Ortopaedkirurgisk Afdeling

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion